U.S. Intravenous Immunoglobulin Is Witnessing High Growth Due To Frequent Launch Of Novel Products In The Region
An immunoglobulin infusion is a type of treatment in which an individual receives a specific amount of an immune system-boosting protein. The goal of this therapy is to maintain high Ig levels in the blood, and the amount of immunoglobulin in the body decreases over time. An infusion is generally repeated every three to four weeks. Although this treatment may seem daunting, it’s actually quite simple.
The process of producing Ig begins with a patient’s plasma, which is tested for the presence of infectious agents. The plasma is then screened for hepatitis B and C markers, as well as HIV. The IgG molecules are separated via various methods of filtration and fractionation. Testing is repeated to ensure that it is safe for use. Additional safety measures may also be implemented. The first step in the production process is to destroy any traces of HIV. In the meantime, no cases of hepatitis C were reported due to Ig replacement therapy.
The U.S. Intravenous Immunoglobulin is expected to grow rapidly during the forecast period. The market for this therapeutic preparation will grow at a steady rate, thanks to the growing incidences of chronic diseases, including immune thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. In the U.S., over 500,000 people are estimated to have some form of primary immunodeficiency. The market is expected to be further buoyed by the growing incidences of autoimmune diseases, such as AIDS.
The therapeutic Ig contains 95–98% pure IgG. However, the Ig used for treatment may contain small amounts of other plasma proteins, including IgA and IgM. A healthcare provider will discuss these risks and benefits with patients before recommending this therapy. In some cases, Ig replacement therapy will reduce the risk of infection and improve quality of life.
There are also many possible adverse effects from IVIG. Although it is generally safe, some people may experience reactions such as a headache, flu, or chills. In rare cases, intravenous immunoglobulin can cause a low blood pressure or a tachycardia. Luckily, most of these effects are minor and should be easily treated by a health professional.
The U.S. Intravenous Immunoglobulin is expected to grow at a faster pace in the near future as more product launches come to market. For instance, Kedrion Biopharma is developing plasma-derived therapies. It has acquired the exclusive rights to commercialize BIVIGAM, a 10% liquid. The Germany-based Biotest Pharmaceuticals Corporation has also licensed the drug. Kedrion Biopharma Inc. is a subsidiary of Kedrion Biopharma. Kedrion is a global leader in the research, development, and manufacturing of therapeutic plasma proteins.
IVIG is composed of four components: the IgG Fc fragment, the variable region F(ab’) 2, the Fc region on the Fc receptors, and the complement-binding Fab domain. The antibodies are then activated by an antigen, causing plasma cells to produce antibodies with the same specificity of their receptor. Although the mechanisms of intravenous immunoglobulin activity differ among individuals, some of them may work simultaneously.
Some studies have shown that intravenous immunoglobulin therapy improves clinical outcomes in asthmatic patients. The optimal dose is 0*6 g/kg. The dosage may vary between individuals. For most patients, however, a lower IVIG dose will produce an improved trough IgG level. Moreover, it is important to follow a protocol for administering this treatment.